<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129829</url>
  </required_header>
  <id_info>
    <org_study_id>WMDH-P34114</org_study_id>
    <nct_id>NCT02129829</nct_id>
  </id_info>
  <brief_title>PROLIFICA - West African Treatment Cohort for Hepatitis B</brief_title>
  <acronym>WATCH</acronym>
  <official_title>Prevention of Liver Fibrosis and Cancer in Africa. Observational Study of Screening, Assessment and Treatment for Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council Unit, The Gambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of State for Health and Social Welfare, The Gambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UFR Sante de Thies, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheikh Anta Diop University, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Agency for Research on Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The West African Treatment Cohort for Hepatitis B (WATCH) study is a component of the
      European Commission Funded FP7 project PROLIFICA. It aims to evaluate a number of steps
      required to successfully treat patients with chronic hepatitis B virus infection to prevent
      cirrhosis and liver cancer. The first step is to determine whether screening for hepatitis B
      using a point of care test is feasible and effective. The second is to monitor linkage from
      screening into care. The third is to evaluate cheap non-invasive assessments to determine the
      need for treatment. The fourth is to determine what proportion of patients meet treatment
      eligibility criteria. The fifth step is to establish a treatment cohort which can be used to
      measure adherence to therapy and avoidance of HBV related complications. A parallel untreated
      cohort will be established to determine whether treatment criteria are relevant in this West
      African setting by monitoring for complications of HBV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives Primary:

      To determine whether suppression of HBV with a nucleotide analogue reduces the risk of liver
      cancer in West African populations.

      Secondary:

      To demonstrate that HBV replication can be effectively suppressed with a nucleotide analogue
      in West African populations To evaluate whether European treatment guidelines are applicable
      in West Africa To establish the applicability and efficacy of population based screening,
      clinical assessment and treatment in West Africa To enumerate the proportion of the adult
      population who carry HBV To evaluate the proportion of the HBV infected population who meet
      European Association for Study of the Liver (EASL) criteria for treatment

      Endpoints Primary:

      Incidence of Hepatocellular Carcinoma over the period of study in a treated cohort of
      patients with chronic HBV compared to historical controls

      Secondary:

      Proportion of adult population in Gambia and Senegal with chronic HBV infection Proportion of
      patients with chronic HBV infection who meet EASL treatment criteria Proportion of patients
      with undetectable HBV DNA &lt; 400 copies/ml at 1, 2, 3, 4 and 5 years of treatment.

      Incidence of hepatocellular Carcinoma in patients who do not meet EASL treatment criteria.

      Treatment adherence rate. Average change in Fibroscan score after 3 and 5 years of treatment
      Emergence of resistance to treatment

      Study Phase 4

      Study Design A two part study:

      Part 1 - Population based screening for HBV infection using a point-of-care test.

      Part 2 - Non-randomised, open label, treatment cohort with parallel observation cohort

      Number of Subjects Part 1:

      Approximately 13,500 adults from the general population.

      Part 2:

      300 subjects in the treatment group 600 subjects in the observation group

      Study Population Part 1:

      Males and females aged over 30 years

      Part 2:

      Patients with chronic hepatitis B virus infection identified through population based
      screening.

      Treatment Cohort There will be a single treatment group of 300 patients who meet EASL
      treatment criteria.

      Schedule of Study Visits Part 1:

      A single visit to an individual at their home or workplace when screening for HBV infection
      will be performed using a point-of-care test..

      Part 2:

      One screening visit will be performed to determine viral load, liver function tests, clinical
      examination, ultrasound examination and liver fibrosis assessment.

      A second visit, 1 - 3 months later, will be used to verify viral load and ALT values

      For those on treatment cohort:

      A baseline visit will take place 2 weeks after the second screening visit and study drug will
      be dispensed with instructions for the patient.

      First follow-up will be at 1 month to check adherence Second follow-up will be at 3 months
      for viral load and liver functions tests Treatment subjects will be seen every 3 months to
      dispense study drug and check compliance Viral load, liver function, renal function, AFP and
      ultrasound will be performed every 6 months.

      Serum/plasma and urine samples for biomarkers of cancer development will be taken at baseline
      and annually.

      Population Screening (Part 1 only) Communities will be sensitised about the study prior to
      visits by fieldworkers to individual homes, places of work or recreational facilities. A
      point-of-care test based on the detection of hepatitis B surface antigen (HBsAg) in a
      finger-prick blood sample will be used for screening. Subjects with a positive test will be
      given a hospital appointment for full clinical assessment.

      Efficacy Evaluations (Part 2 only) Detection of liver cancer - Surveillance for liver cancer
      will be made using ultrasound and serum AFP every 6 months on all subjects. In some centres
      further imaging will be available.

      Liver cancer will be diagnosed according to the following criteria:

        -  Liver mass with typical features of hepatocellular carcinoma on two imaging modalities
           (ultrasound, bubble ultrasound or CT), or

        -  liver mass on ultrasound and AFP &gt; 400 iu/ml or

        -  histological or cytological confirmation of diagnosis.

      Viral Load - viral load will be measure on EDTA plasma samples using an in-house real-time
      PCR assay verified for accuracy against commercial assays every 6 months.

      Safety Evaluations (Part 2 only) Liver function tests, serum phosphate and renal function
      will be tested every 6 months

      Evaluation of treatment guidelines Subjects who do not meet the EASL treatment criteria at
      baseline will be enrolled in the observational study with surveillance for liver cancer every
      6 months

      Detection of viral resistance Viral load monitoring of patients in the treatment study every
      6 months will be used to detect possible virological resistance. A rise in viral load from
      nadir values or reappearance of detectable viraemia in patients who had achieved undetectable
      viral load will be investigated for emergence of viral sequence variants and for adherence to
      therapy
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HCC or decompensated cirrhosis</measure>
    <time_frame>5 years</time_frame>
    <description>Subjects will be reviewed 6 monthly with liver biochemistry and ultrasound to detect onset of hepatocellular carcinoma or decompensated cirrhosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uptake of screening</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of community subjects who accept screening tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of HBV infection</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients who test positive for HBsAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of linkage into care</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients who test positive for HBsAg who attend clinic for assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment rate</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with HBsAg who meet EASL treatment criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reliability of PoC test</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitivity and specificity of capillary blood sample HBsAg test applied at point of care</description>
  </other_outcome>
  <other_outcome>
    <measure>Accuracy of non-invasive fibrosis assessment</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitivity, specificity and ROC analysis of Fibroscan, APRI and FIB4 tests compared to liver biopsy to assess liver fibrosis</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1079</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Observational Group</arm_group_label>
    <description>Patients whose viral load, ALT value and fibrosis status does not meet EASL criteria for treatment and are observed 6 monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group (Tenofovir disoproxil)</arm_group_label>
    <description>Patients who meet EASL treatment criteria who receive Tenofovir disoproxil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Tenofovir disoproxil 245 mg once daily</description>
    <arm_group_label>Treatment Group (Tenofovir disoproxil)</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, urine and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All adults are included for community screening. Selection criteria (below) are applied for
        recruitment into cohorts
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Informed consent HBsAg positive Resident in Gambia or Senegal

        Exclusion Criteria:

          -  HIV infection HCV infection Known liver cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Thursz, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MRC Laboratories Hospital</name>
      <address>
        <city>Fajara</city>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UFR Sante Thies,</name>
      <address>
        <city>Thies</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gambia</country>
    <country>Senegal</country>
  </location_countries>
  <reference>
    <citation>Lemoine M, Shimakawa Y, Njie R, Njai HF, Nayagam S, Khalil M, Goldin R, Ingiliz P, Taal M, Nyan O, Corrah T, D'Alessandro U, Thursz M. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther. 2014 Jan;39(2):188-96. doi: 10.1111/apt.12561. Epub 2013 Dec 5.</citation>
    <PMID>24308698</PMID>
  </reference>
  <reference>
    <citation>Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, Ghosh S, Njai HF, Jeng A, Sow A, Toure-Kane C, Mboup S, Suso P, Tamba S, Jatta A, Sarr L, Kambi A, Stanger W, Nayagam S, Howell J, Mpabanzi L, Nyan O, Corrah T, Whittle H, Taylor-Robinson SD, D'Alessandro U, Mendy M, Thursz MR; PROLIFICA investigators. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health. 2016 Aug;4(8):e559-67. doi: 10.1016/S2214-109X(16)30130-9.</citation>
    <PMID>27443781</PMID>
  </reference>
  <reference>
    <citation>Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, Thursz M. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health. 2016 Aug;4(8):e568-78. doi: 10.1016/S2214-109X(16)30101-2. Erratum in: Lancet Glob Health. 2016 Nov;4(11):e794.</citation>
    <PMID>27443782</PMID>
  </reference>
  <reference>
    <citation>Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin Infect Dis. 2020 Mar 17;70(7):1442-1452. doi: 10.1093/cid/ciz412.</citation>
    <PMID>31102406</PMID>
  </reference>
  <reference>
    <citation>Shimakawa Y, Njie R, Ndow G, Vray M, Mbaye PS, Bonnard P, Sombié R, Nana J, Leroy V, Bottero J, Ingiliz P, Post G, Sanneh B, Baldeh I, Suso P, Ceesay A, Jeng A, Njai HF, Nayagam S, D'Alessandro U, Chemin I, Mendy M, Thursz M, Lemoine M. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. J Hepatol. 2018 Oct;69(4):776-784. doi: 10.1016/j.jhep.2018.05.024. Epub 2018 Jul 1.</citation>
    <PMID>30104154</PMID>
  </reference>
  <reference>
    <citation>Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, Goldin R, Njai HF, Ndow G, Taal M, Cooke G, D'Alessandro U, Vray M, Mbaye PS, Njie R, Mallet V, Thursz M. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016 Aug;65(8):1369-76. doi: 10.1136/gutjnl-2015-309260. Epub 2015 Jun 24.</citation>
    <PMID>26109530</PMID>
  </reference>
  <reference>
    <citation>Shimakawa Y, Lemoine M, Bottomley C, Njai HF, Ndow G, Jatta A, Tamba S, Bojang L, Taal M, Nyan O, D'Alessandro U, Njie R, Thursz M, Hall AJ. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. Liver Int. 2015 Oct;35(10):2318-26. doi: 10.1111/liv.12814. Epub 2015 Mar 11.</citation>
    <PMID>25728498</PMID>
  </reference>
  <reference>
    <citation>Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M, Sow A, Lo G, Toure-Kane C, Tanaka J, Taal M, D'alessandro U, Njie R, Thursz M, Lemoine M. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J Clin Microbiol. 2015 Apr;53(4):1156-63. doi: 10.1128/JCM.02980-14. Epub 2015 Jan 28.</citation>
    <PMID>25631805</PMID>
  </reference>
  <reference>
    <citation>Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, Jatta A, Jeng-Barry A, Wegmuller R, Moore SE, Baldeh I, Taal M, D'Alessandro U, Whittle H, Njie R, Thursz M, Mendy M. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016 Dec;65(12):2007-2016. doi: 10.1136/gutjnl-2015-309892. Epub 2015 Jul 16.</citation>
    <PMID>26185161</PMID>
  </reference>
  <reference>
    <citation>Shimakawa Y, Lemoine M, Mendy M, Njai HF, D'Alessandro U, Hall A, Thursz M, Njie R. Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the gambia, west Africa. Trop Med Health. 2014 Jun;42(2 Suppl):59-64. doi: 10.2149/tmh.2014-S08.</citation>
    <PMID>25425952</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>HBV</keyword>
  <keyword>HIV</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

